Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga

Antiviral therapeutics with existing clinical safely profiles would be highly desirable in an outbreak situation, such as the 2013-2016 emergence of Ebola virus (EBOV) in West Africa. Although, the World Health Organization declared the end of the outbreak early 2016, sporadic cases of EBOV infectio...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 214; no. suppl 3; pp. S355 - S359
Main Authors Chiramel, Abhilash I., Banadyga, Logan, Dougherty, Jonathan D., Falzarano, Darryl, Martellaro, Cynthia, Brees, Dominique, Taylor, R. Travis, Ebihara, Hideki, Best, Sonja M.
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 15.10.2016
Subjects
Africa, Western - epidemiology
Antiviral Agents - therapeutic use
Cyclosporine - therapeutic use
Disease Outbreaks
Ebola Outbreak in West Africa
Ebolavirus - drug effects
Hemorrhagic Fever, Ebola - drug therapy
Hemorrhagic Fever, Ebola - virology
Humans
MEDICAL COUNTERMEASURES
Virus Replication
Ebola virus
antivirals
alisporivir
cyclophilin A
flavivirus
Online AccessGet full text

Cover

Abstract Antiviral therapeutics with existing clinical safely profiles would be highly desirable in an outbreak situation, such as the 2013-2016 emergence of Ebola virus (EBOV) in West Africa. Although, the World Health Organization declared the end of the outbreak early 2016, sporadic cases of EBOV infection have since been reported. Alisporivir is the most clinically advanced broad-spectrum antiviral that functions by targeting a host protein, cyclophilin A (CypA). A modest antiviral effect of alisporivir against contemporary (Makona) but not historical (Mayinga) EBOV strains was observed in tissue culture. However, this effect was not comparable to observations for an alisporivir-susceptible virus, the flavivirus tick-borne encephalitis virus. Thus, EBOV does not depend on (CypA) for replication, in contrast to many other viruses pathogenic to humans.
AbstractList Antiviral therapeutics with existing clinical safety profiles would be highly desirable in an outbreak situation, such as the 2013–2016 emergence of Ebola virus (EBOV) in West Africa. Although, the World Health Organization declared the end of the outbreak early 2016, sporadic cases of EBOV infection have since been reported. Alisporivir is the most clinically advanced broad-spectrum antiviral that functions by targeting a host protein, cyclophilin A (CypA). A modest antiviral effect of alisporivir against contemporary (Makona) but not historical (Mayinga) EBOV strains was observed in tissue culture. However, this effect was not comparable to observations for an alisporivir-susceptible virus, the flavivirus tick-borne encephalitis virus. Thus, EBOV does not depend on (CypA) for replication, in contrast to many other viruses pathogenic to humans.
Antiviral therapeutics with existing clinical safely profiles would be highly desirable in an outbreak situation, such as the 2013-2016 emergence of Ebola virus (EBOV) in West Africa. Although, the World Health Organization declared the end of the outbreak early 2016, sporadic cases of EBOV infection have since been reported. Alisporivir is the most clinically advanced broad-spectrum antiviral that functions by targeting a host protein, cyclophilin A (CypA). A modest antiviral effect of alisporivir against contemporary (Makona) but not historical (Mayinga) EBOV strains was observed in tissue culture. However, this effect was not comparable to observations for an alisporivir-susceptible virus, the flavivirus tick-borne encephalitis virus. Thus, EBOV does not depend on (CypA) for replication, in contrast to many other viruses pathogenic to humans.
Author Banadyga, Logan
Chiramel, Abhilash I.
Falzarano, Darryl
Ebihara, Hideki
Dougherty, Jonathan D.
Martellaro, Cynthia
Best, Sonja M.
Brees, Dominique
Taylor, R. Travis
Author_xml – sequence: 1
  givenname: Abhilash I.
  surname: Chiramel
  fullname: Chiramel, Abhilash I.
– sequence: 2
  givenname: Logan
  surname: Banadyga
  fullname: Banadyga, Logan
– sequence: 3
  givenname: Jonathan D.
  surname: Dougherty
  fullname: Dougherty, Jonathan D.
– sequence: 4
  givenname: Darryl
  surname: Falzarano
  fullname: Falzarano, Darryl
– sequence: 5
  givenname: Cynthia
  surname: Martellaro
  fullname: Martellaro, Cynthia
– sequence: 6
  givenname: Dominique
  surname: Brees
  fullname: Brees, Dominique
– sequence: 7
  givenname: R. Travis
  surname: Taylor
  fullname: Taylor, R. Travis
– sequence: 8
  givenname: Hideki
  surname: Ebihara
  fullname: Ebihara, Hideki
– sequence: 9
  givenname: Sonja M.
  surname: Best
  fullname: Best, Sonja M.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27511894$$D View this record in MEDLINE/PubMed
BookMark eNp1UU1vEzEQtaoimqYcewT5yGWpv_bDl0pRFShSEAco4mZ5_REmbOzUdor679lo2woq9TSj5zfvjeedouMQg0PonJIPlEh-AcFbyBcb-MMEPUIzWvO2ahrKj9GMEMYq2kl5gk5z3hBCBG_a1-iEtTUdcTFDPxcD5F1McAcJX-uMV7CF4ixehHLA9ICX3jtTMl6sNYRc8LKPg8Y_IO0z_lbSAcRf9O8YNNbBju09hLU-Q6-8HrJ781Dn6Obj8vvVdbX6-unz1WJVGUFkqZhmupe8M633zHaMciuN7b1oBPWOkqal4zeZpbXjrutky3zPhGwM9cKyRvI5upx0d_t-66xxYVxpULsEW53uVdSg_n8J8Eut452qSU1ES0eB9w8CKd7uXS5qC9m4YdDBxX1WtOM1r0U3HnaO3v3r9WTyeM6RwCeCSTHn5LwyUHSBeLCGQVGiDqGpKTQ1hTZOVc-mHoVf4r-d-JtcYnoiC0FIywnhfwH4KKaB
CitedBy_id crossref_primary_10_1002_ange_202201597
crossref_primary_10_1016_j_celrep_2019_05_040
crossref_primary_10_1016_j_antiviral_2025_106101
crossref_primary_10_1128_AAC_00126_18
crossref_primary_10_1002_anie_202201597
crossref_primary_10_3389_fimmu_2018_01803
Cites_doi 10.1371/journal.ppat.1004422
10.1016/j.chom.2011.08.004
10.1126/science.aaa3778
10.1016/j.antiviral.2011.05.006
10.1126/science.aab3920
10.1128/AAC.00189-09
10.1128/AAC.00016-14
10.1016/j.antiviral.2015.12.006
10.1038/clpt.2014.173
10.1002/hep.26989
10.1038/nature13027
10.1038/nature17180
10.3390/v5071684
10.1128/JVI.02701-15
10.1021/jm500223x
10.7883/yoken.66.276
10.1128/JVI.01876-08
ContentType Journal Article
Copyright Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US. 2016
Copyright_xml – notice: Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
– notice: Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US. 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1093/infdis/jiw241
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1537-6613
EndPage S359
ExternalDocumentID PMC5050471
27511894
10_1093_infdis_jiw241
44007300
Genre Journal Article
Research Support, N.I.H., Intramural
GrantInformation_xml – fundername: ;
GroupedDBID ---
-DZ
-~X
..I
.2P
.I3
.XZ
.ZR
08P
0R~
123
1KJ
1TH
29K
2AX
2WC
36B
4.4
48X
53G
5GY
5RE
5VS
5WD
70D
85S
AABZA
AACGO
AACZT
AAHBH
AAHTB
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWTL
ABBHK
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPLY
ABPPZ
ABPQP
ABPTD
ABQLI
ABQNK
ABTLG
ABVGC
ABWST
ABXSQ
ABXVV
ABZBJ
ACGFO
ACGFS
ACGOD
ACHIC
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADQXQ
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFZL
AFIYH
AFOFC
AFXAL
AFYAG
AGINJ
AGKEF
AGORE
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQVQM
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BR6
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
D-I
DAKXR
DCCCD
DIK
DILTD
DU5
D~K
EBS
ECGQY
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IH2
IOX
IPSME
J21
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
LSO
LU7
MHKGH
MJL
ML0
N9A
NGC
NOMLY
NOYVH
NU-
NVLIB
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TR2
W2D
W8F
WH7
X7H
YAYTL
YKOAZ
YXANX
~91
AAYXX
CITATION
ADJQC
ADRIX
AFXEN
CGR
CUY
CVF
DOOOF
ECM
EIF
ESX
M49
NPM
YIF
7X8
5PM
ID FETCH-LOGICAL-c409t-2a2ab938c7ff2d8213d9cdbf4641fe106711092d15e3e88972fb2496c1f4d2693
ISSN 0022-1899
IngestDate Thu Aug 21 18:26:05 EDT 2025
Thu Jul 10 16:36:27 EDT 2025
Wed Feb 19 02:43:39 EST 2025
Tue Jul 01 01:31:03 EDT 2025
Thu Apr 24 23:09:18 EDT 2025
Thu Jun 19 23:15:08 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue suppl 3
Keywords Ebola virus
antivirals
alisporivir
cyclophilin A
flavivirus
Language English
License Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c409t-2a2ab938c7ff2d8213d9cdbf4641fe106711092d15e3e88972fb2496c1f4d2693
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/jid/article-pdf/214/suppl_3/S355/7936147/jiw241.pdf
PMID 27511894
PQID 1835354815
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5050471
proquest_miscellaneous_1835354815
pubmed_primary_27511894
crossref_citationtrail_10_1093_infdis_jiw241
crossref_primary_10_1093_infdis_jiw241
jstor_primary_44007300
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-10-15
PublicationDateYYYYMMDD 2016-10-15
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of infectious diseases
PublicationTitleAlternate J Infect Dis
PublicationYear 2016
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References 2016120500053896000_214.suppl_3.S355.6
2016120500053896000_214.suppl_3.S355.7
2016120500053896000_214.suppl_3.S355.8
Alfson (2016120500053896000_214.suppl_3.S355.2) 2015; 90
2016120500053896000_214.suppl_3.S355.9
2016120500053896000_214.suppl_3.S355.10
2016120500053896000_214.suppl_3.S355.12
2016120500053896000_214.suppl_3.S355.11
2016120500053896000_214.suppl_3.S355.3
2016120500053896000_214.suppl_3.S355.17
2016120500053896000_214.suppl_3.S355.4
2016120500053896000_214.suppl_3.S355.5
2016120500053896000_214.suppl_3.S355.14
2016120500053896000_214.suppl_3.S355.13
2016120500053896000_214.suppl_3.S355.16
2016120500053896000_214.suppl_3.S355.1
2016120500053896000_214.suppl_3.S355.15
25883340 - Science. 2015 Apr 17;348(6232):282-3
24375768 - Hepatology. 2014 May;59(5):1706-14
26676781 - J Virol. 2015 Dec 16;90(5):2345-55
26934220 - Nature. 2016 Mar 17;531(7594):381-5
24687498 - Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34
24590073 - Nature. 2014 Apr 17;508(7496):402-5
23852270 - Viruses. 2013 Jul 11;5(7):1684-701
26711718 - Antiviral Res. 2016 Feb;126:62-8
19073742 - J Virol. 2009 Feb;83(4):2044-7
25166216 - Clin Pharmacol Ther. 2014 Nov;96(5):599-608
26249231 - Science. 2015 Aug 14;349(6249):739-42
23883836 - Jpn J Infect Dis. 2013;66(4):276-83
24831536 - J Med Chem. 2014 Sep 11;57(17):7145-59
19451286 - Antimicrob Agents Chemother. 2009 Aug;53(8):3226-35
25275585 - PLoS Pathog. 2014 Oct 02;10(10):e1004422
21925107 - Cell Host Microbe. 2011 Sep 15;10(3):185-96
21616094 - Antiviral Res. 2011 Aug;91(2):89-93
References_xml – ident: 2016120500053896000_214.suppl_3.S355.11
  doi: 10.1371/journal.ppat.1004422
– ident: 2016120500053896000_214.suppl_3.S355.14
  doi: 10.1016/j.chom.2011.08.004
– ident: 2016120500053896000_214.suppl_3.S355.10
  doi: 10.1126/science.aaa3778
– ident: 2016120500053896000_214.suppl_3.S355.3
  doi: 10.1016/j.antiviral.2011.05.006
– ident: 2016120500053896000_214.suppl_3.S355.13
  doi: 10.1126/science.aab3920
– ident: 2016120500053896000_214.suppl_3.S355.15
  doi: 10.1128/AAC.00189-09
– ident: 2016120500053896000_214.suppl_3.S355.17
  doi: 10.1128/AAC.00016-14
– ident: 2016120500053896000_214.suppl_3.S355.1
  doi: 10.1016/j.antiviral.2015.12.006
– ident: 2016120500053896000_214.suppl_3.S355.9
  doi: 10.1038/clpt.2014.173
– ident: 2016120500053896000_214.suppl_3.S355.8
  doi: 10.1002/hep.26989
– ident: 2016120500053896000_214.suppl_3.S355.4
  doi: 10.1038/nature13027
– ident: 2016120500053896000_214.suppl_3.S355.5
  doi: 10.1038/nature17180
– ident: 2016120500053896000_214.suppl_3.S355.6
  doi: 10.3390/v5071684
– volume: 90
  start-page: 2345
  year: 2015
  ident: 2016120500053896000_214.suppl_3.S355.2
  article-title: Determination and therapeutic exploitation of ebola virus spontaneous mutation frequency
  publication-title: J Virol
  doi: 10.1128/JVI.02701-15
– ident: 2016120500053896000_214.suppl_3.S355.7
  doi: 10.1021/jm500223x
– ident: 2016120500053896000_214.suppl_3.S355.16
  doi: 10.7883/yoken.66.276
– ident: 2016120500053896000_214.suppl_3.S355.12
  doi: 10.1128/JVI.01876-08
– reference: 24375768 - Hepatology. 2014 May;59(5):1706-14
– reference: 25883340 - Science. 2015 Apr 17;348(6232):282-3
– reference: 26711718 - Antiviral Res. 2016 Feb;126:62-8
– reference: 26249231 - Science. 2015 Aug 14;349(6249):739-42
– reference: 19451286 - Antimicrob Agents Chemother. 2009 Aug;53(8):3226-35
– reference: 23883836 - Jpn J Infect Dis. 2013;66(4):276-83
– reference: 24687498 - Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34
– reference: 25166216 - Clin Pharmacol Ther. 2014 Nov;96(5):599-608
– reference: 23852270 - Viruses. 2013 Jul 11;5(7):1684-701
– reference: 21616094 - Antiviral Res. 2011 Aug;91(2):89-93
– reference: 26676781 - J Virol. 2015 Dec 16;90(5):2345-55
– reference: 25275585 - PLoS Pathog. 2014 Oct 02;10(10):e1004422
– reference: 21925107 - Cell Host Microbe. 2011 Sep 15;10(3):185-96
– reference: 24831536 - J Med Chem. 2014 Sep 11;57(17):7145-59
– reference: 24590073 - Nature. 2014 Apr 17;508(7496):402-5
– reference: 26934220 - Nature. 2016 Mar 17;531(7594):381-5
– reference: 19073742 - J Virol. 2009 Feb;83(4):2044-7
SSID ssj0004367
Score 2.2440739
Snippet Antiviral therapeutics with existing clinical safely profiles would be highly desirable in an outbreak situation, such as the 2013-2016 emergence of Ebola...
Antiviral therapeutics with existing clinical safety profiles would be highly desirable in an outbreak situation, such as the 2013-2016 emergence of Ebola...
Antiviral therapeutics with existing clinical safety profiles would be highly desirable in an outbreak situation, such as the 2013–2016 emergence of Ebola...
SourceID pubmedcentral
proquest
pubmed
crossref
jstor
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage S355
SubjectTerms Africa, Western - epidemiology
Antiviral Agents - therapeutic use
Cyclosporine - therapeutic use
Disease Outbreaks
Ebola Outbreak in West Africa
Ebolavirus - drug effects
Hemorrhagic Fever, Ebola - drug therapy
Hemorrhagic Fever, Ebola - virology
Humans
MEDICAL COUNTERMEASURES
Virus Replication
Title Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga
URI https://www.jstor.org/stable/44007300
https://www.ncbi.nlm.nih.gov/pubmed/27511894
https://www.proquest.com/docview/1835354815
https://pubmed.ncbi.nlm.nih.gov/PMC5050471
Volume 214
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELeqIRAvCAaD8iUjIV5CtsZ2vh6rblUHFCGxob5Fjp2sQSWduhbU_fXcxU6aTgXBXqLWteO298v5zr77HSFvlVAyiEXqKhlnrgi0dtMoClw_55kIVCozhbnD48_B6Fx8mPiTTqfNELxapofqemdeyW2kCm0gV8yS_Q_JNjeFBngN8oUrSBiu_yTj_qxAr7T4WSyckbyqs5WQEQDbkDLYhmv0L2QBhqBzkoIr63wrFqsrPJDGRmcswUiUNuICs55k22Ld5I5ZegkTvAXj7dlOY5QPpgVGeplT_3RagF0-dU4PN3ulpdRrs4_7aX6xQSXa8FOk-G3v5jvHzcChnF1LWFLnJgZ_sVjP2nsVXoBK3mRr_i0Hsq2fwTX2IlMy6TCrVXLoghXB2zqbmcxTC86qAKrDW3r4Kzfkv3ZNh7fxzvXCcGlBk0ZGh-H34hczPFwt9Fz-qODDQnTGTEXmGxTdX8YDMCR7ArkM7jDwV7CUxvHpx02CLg_CmrYef54le4XZj8zcR2ZmpKa202zZSSZUdpcTdDOWt2UcnT0kDyw-aN9A9BHpZOU-uWvqnK73yb2xjeB4TCYtzFLALLWYpQ1mqcUstZilFWZphVlqMUsNZilgllrMPiHnw5Ozwci11T1cJXrx0mWSyTTmkQrznOmIeVzHSqe5CISXZ8hsiGS4THt-xrMoikOWp0zEgfJyoVkQ8wOyV87L7BmhCtz2CJkjwVsR4M9EDNwgrVNfx6GvVK9L3tf_ZaIs9T1-3VliQjB4YqSQGCl0ybum-6XhfPlTx4NKME0vIXpVAYgueVNLKgF1jWdwsszg0UxgBfW5jwxJXfLUSK4ZXYu-S8ItmTYdkAp--5OymFaU8BZ-z2898gW5v3lgX5K95WKVvQJze5m-rqD8G31A3Pk
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alisporivir+Has+Limited+Antiviral+Effects+Against+Ebola+Virus+Strains+Makona+and+Mayinga&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Chiramel%2C+Abhilash+I.&rft.au=Banadyga%2C+Logan&rft.au=Dougherty%2C+Jonathan+D.&rft.au=Falzarano%2C+Darryl&rft.date=2016-10-15&rft.pub=Oxford+University+Press&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=214&rft.issue=Suppl+3&rft.spage=S355&rft.epage=S359&rft_id=info:doi/10.1093%2Finfdis%2Fjiw241&rft_id=info%3Apmid%2F27511894&rft.externalDocID=PMC5050471
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon